VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

MDS 2021 | The use of amantadine in Parkinson’s disease

Caroline Tanner, MD, PhD, FAAN, Weill Institute for Neurosciences, University of California, San Francisco, CA, talks on the use of amantadine in Parkinson’s disease. Initially, the drug was used as a prophylactic agent against influenza, serendipitously discovered to have anti-parkinsonian effects. Amantadine is an oral NMDA receptor antagonist and was the first agent approved by the FDA for the treatment of levodopa-induced dyskinesia following demonstration of its anti-dyskinetic effects. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.